http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103340864-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_52161dbeae9abc88ea5e7a6b9d856732 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473 |
| filingDate | 2013-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e244b0f40c4f7e6d47fd0492455dcfa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a88f4edaa9b42c92ea9b76f5e9f8e60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afdd83727374211db0a2b5700635fe25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf8e9af8bc064f49d9a67f05179ee393 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7de0ea56a7d0de30f8a1e62f689174f |
| publicationDate | 2013-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103340864-A |
| titleOfInvention | Palonosetron composition for injection |
| abstract | The invention provides a palonosetron composition for injection and relates to the technical field of medicaments and medicament manufacturing. The main medicaments of the composition are palonosetron and melatonin, wherein the melatonin comprises a quick release part and a slow release part contained in cyclodextrin. The palonosetron composition for injection provided by the invention can be used for improving the treatment effect of the palonosetron, avoiding instability, quick distribution and elimination and the like of MT ((Metal Thionein) caused by oral absorption, reducing the first-pass effect of the MT and reducing the dosage of the palonosetron; The medicament administration design combining the quick release with the slow release satisfies physiological secretion characteristics of the MT, can be used for solving the problem that the half-life period of the MT is short, increasing the biological utilization rate of the palonosetron composition, and achieving the synergism of the palonosetron for treating CINV (Chemotherapy Induced Nausea And Vomiting). The quick release part and the slow release part are combined, so that not only can the CINV be treated, but also the treatment effect of the palonosetron on the CINV can be improved, and therefore, the treatment course is shortened, the dosage of the palonosetron is reduced, the side effect of the palonosetron is lowered, and the body immunity can be improved. A certain concentration of melatonin is kept in the blood of the human body, so that the stress response of the organisms can be effectively lowered for facilitating the treatment of the CINV. |
| priorityDate | 2013-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.